PARTNERING WITH SANGAMO

Sangamo values partnerships with companies that share our mission of translating ground-breaking science into genomic medicines that transform patients’ lives. We seek collaborations that can leverage and extend our leading capabilities in gene therapy, cell therapy, genome editing, and genome regulation.

 

Interested in Partnering with Us?

Click here to contact Mark McClung, Executive Vice President, Chief Business Officer.

OUR PARTNERS

Biogen

Biogen and Sangamo have a global licensing collaboration agreement to develop and commercialize ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, a third undisclosed neuromuscular disease target, and up to nine additional undisclosed neurological disease targets.

Kite, a Gilead Company

Kite, a Gilead Company, and Sangamo are developing next-generation ex vivo cell therapies to treat cancer by using Sangamo’s zinc finger nuclease (ZFN) technology.

Novartis

Novartis and Sangamo have a global licensing collaboration agreement to develop and commercialize gene regulation therapies to address neurodevelopmental targets, including genes linked to autism spectrum disorder and other neurodevelopmental disorders.

Pfizer Inc.

Pfizer and Sangamo have an exclusive, global collaboration and license agreement to develop and commercialize gene therapies for hemophilia. 

Sangamo and Pfizer are also collaborating for the development and commercialization of therapeutics using our zinc finger protein transcription factors (ZFP-TFs) to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene.

Sanofi

Sanofi and Sangamo are developing gene-edited cell therapies for the treatment of beta thalassemia and sickle cell disease, using Sangamo’s zinc finger nuclease technology.

Takeda Pharmaceutical Company Limited

Takeda and Sangamo are developing therapeutics for Huntington's disease utilizing our ZFP-TF genome regulation platform.